Tri-Heal 45 mg Blend

Healing & recovery Research compound (not approved for human use)

Tissue-repair and anti-inflammatory blend (three peptides) · also known as TB-500 + BPC-157 + KPV

For reference only — not medical advice. Figures are commonly reported values compiled from published sources and may be wrong or out of date. Many compounds listed are not approved for human use. Talk to a licensed clinician before using any compound.

Tri-Heal combines TB-500 and BPC-157 with the anti-inflammatory tripeptide KPV in a 25 : 10 : 10 mass ratio. The reported schedule steps the total amount up every two weeks, with optional extension to 12 or 16 weeks.

Commonly reported dosing (45 mg vial)

Reconstituted with 3 mL → 15 mg/mL.

Phase	Dose	Volume	U-100 units
Starting Weeks 1-2, total blend	500 mcg	0.033 mL	3.3
Standard Weeks 5-6, total blend	1.5 mg	0.1 mL	10
Higher Weeks 7-8, total blend; extended 12- and 16-week schedules continue to 3000-4000	2 mg	0.133 mL	13.3

Each 500 mcg draw contains 277.8 mcg TB-500 + 111.1 mcg BPC-157 + 111.1 mcg KPV.

Frequency: Once daily, subcutaneous · Half-life: Mixed (see individual peptides)

Open in calculator

Commonly reported dose escalation

Weeks	Dose	Volume	U-100 units
Weeks 1-2	500 mcg	0.033 mL	3.3
Weeks 3-4	1 mg	0.067 mL	6.7
Weeks 5-6	1.5 mg	0.1 mL	10
Weeks 7-8	2 mg	0.133 mL	13.3
Weeks 9-10	2.5 mg	0.167 mL	16.7
Weeks 11-12	3 mg	0.2 mL	20
Weeks 13-14	3.5 mg	0.233 mL	23.3
Week 15+	4 mg	0.267 mL	26.7

Higher steps may need a larger vial or more than one draw. Escalation schedules vary; dosing decisions belong to a licensed clinician.

Commonly reported reconstitution steps

Vials are usually brought to room temperature (about 15-20 minutes) first.
3 mL of bacteriostatic water is added slowly down the inside wall of the 45 mg vial.
The vial is swirled gently until clear, not shaken.
This gives 15 mg/mL. Mixed vials are typically labeled with the date and refrigerated.

Storage

Before mixing: Sealed vials are commonly stored refrigerated (2-8 °C) and protected from light, or frozen for long-term storage.

After mixing: Reconstituted solution is commonly kept refrigerated (2-8 °C), protected from light, and not frozen.

Commonly used within 28 days of mixing.

How it works

TB-500, a thymosin beta-4 fragment, is associated with actin binding, cell migration and angiogenesis. BPC-157 is linked to angiogenesis and growth-factor signaling, and KPV is an alpha-MSH fragment studied for NF-kB-related anti-inflammatory effects.

Researched for

Studied per component in animal models of tendon, muscle, gut and wound repair.
Investigated as a combined repair-plus-inflammation research protocol.

Notes

No controlled human trial has tested this three-peptide mixture; evidence is per component and mostly preclinical.
Because it is a blend, the per-dose amount covers all three peptides in a 5:2:2 ratio.
Reconstituted solution is commonly refrigerated.

Sources

Last reviewed 2026-10-06.

TB-500

Thymosin beta-4 fragment

TB-500 is a synthetic version of a region of the naturally occurring protein thymosin beta-4.

5 mg vial · Once daily, subcutaneous (a weekly loading pattern is also reported)

BPC-157

Synthetic pentadecapeptide

BPC-157 is a synthetic peptide derived from a sequence found in gastric juice.

5 mg vial · Once daily, subcutaneous (some reports split it into two injections)

KPV

Tripeptide fragment of α-MSH

KPV is the three-amino-acid C-terminal sequence of alpha-MSH, studied mainly for anti-inflammatory activity in gut and skin models.

10 mg vial · Once daily, subcutaneous

BPC-157 + TB-500 20 mg Blend

Tissue-repair research blend (BPC-157 + TB-500)

This blend combines BPC-157 and TB-500 in a single vial (20 mg by default, with a 10 mg size also listed), a common pairing in recovery-oriented research because the two peptides are studied for complementary roles in tissue-repair research.

20 mg vial · Once daily, subcutaneous